EBR:MDXH - Euronext Brussels - BE0974461940 - Common Stock - Currency: EUR
EBR:MDXH (12/15/2023, 7:00:00 PM)
3.02
-0.12 (-3.76%)
The current stock price of MDXH.BR is 3.02 EUR. In the past month the price increased by 5.19%. In the past year, price increased by 381.66%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 19.07 | 305.33B | ||
1ABBV.MI | ABBVIE INC | 18.36 | 294.00B | ||
AMG.DE | AMGEN INC | 13.41 | 131.91B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.7 | 116.36B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1709.42 | 114.26B | ||
GIS.DE | GILEAD SCIENCES INC | 13.22 | 112.29B | ||
ARGX.BR | ARGENX SE | 378.56 | 35.37B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.35B | ||
IDP.DE | BIOGEN INC | 7.73 | 15.80B | ||
1MRNA.MI | MODERNA INC | N/A | 9.49B | ||
0QF.DE | MODERNA INC | N/A | 9.43B | ||
BIO.DE | BIOTEST AG | 64.92 | 1.67B |
MDxHealth SA is a BE-based company operating in Biotechnology industry. The company is headquartered in Herstal, Liege and currently employs 258 full-time employees. The company went IPO on 2006-06-26. MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
MDxHealth SA
CAP Business Center, Rue d'Abhooz 31
Herstal LIEGE BE
Employees: 258
Phone: 3243642070
The current stock price of MDXH.BR is 3.02 EUR. The price decreased by -3.76% in the last trading session.
The exchange symbol of MDxHealth SA is MDXH and it is listed on the Euronext Brussels exchange.
MDXH.BR stock is listed on the Euronext Brussels exchange.
9 analysts have analysed MDXH.BR and the average price target is 8.4 EUR. This implies a price increase of 178.05% is expected in the next year compared to the current price of 3.02. Check the MDxHealth SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MDxHealth SA (MDXH.BR) has a market capitalization of 82.41M EUR. This makes MDXH.BR a Micro Cap stock.
MDxHealth SA (MDXH.BR) currently has 258 employees.
MDxHealth SA (MDXH.BR) has a support level at 2.82. Check the full technical report for a detailed analysis of MDXH.BR support and resistance levels.
The Revenue of MDxHealth SA (MDXH.BR) is expected to grow by 84.81% in the next year. Check the estimates tab for more information on the MDXH.BR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MDXH.BR does not pay a dividend.
MDxHealth SA (MDXH.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.68).
ChartMill assigns a technical rating of 8 / 10 to MDXH.BR. When comparing the yearly performance of all stocks, MDXH.BR is one of the better performing stocks in the market, outperforming 99.77% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to MDXH.BR. Both the profitability and financial health of MDXH.BR have multiple concerns.
Over the last trailing twelve months MDXH.BR reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -16.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -51.61% | ||
ROE | -393.48% | ||
Debt/Equity | 2.17 |
ChartMill assigns a Buy % Consensus number of 87% to MDXH.BR. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -6519.8% and a revenue growth 84.81% for MDXH.BR